(15) found that patients with favorable high-risk prostate cancer (stage T1c with Gleason 4 + 4 = 8 and PSA <10 ng/ml or stage T1c with Gleason 6 and PSA >20 ng/ml) have significantly better PCSM than other patients with high-risk disease and similar PCSM as those with unfavorable intermediate-risk disease, who are typically treated with shorter-course androgen deprivation therapy. Here, KLK3 is linked to prostate cancer.